Try these hidden ‘NOPE' buttons to stop AI content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth
The global cell and gene therapy supply chain software market is set to expand from USD 0.27 billion in 2025 to USD 1.32 billion by 2035, at a CAGR of 15.2%. Driven by demand for advanced therapies, the market is enhanced by cloud-based technologies and key players like Azenta Life Sciences and Lonza. Cell and Gene Therapy Supply Chain Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to offering. The global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in 2025, to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, to 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies. The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems. Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users. The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023. Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years. Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future. The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including process component, type of software, mode of deployment, scale of operation and key geographical regions. Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as type of software, key features, application area, mode of deployment, scale of operation, regulatory guidelines followed and type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and most active players based on the number of software solutions offered. Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as developer strength and product portfolio strength. Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on company overviews, software solutions portfolio, financial information, recent developments and an informed future outlook. Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings. Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements. Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain. Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs. Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth. Sample Players in the Cell and Gene Therapy Supply Chain Software Market, Profiled in the Report Include: Azenta Life Sciences Biocair BioLife Solutions CareDx Cryoport Lonza NMDP BioTherapies TraceLink TrakCel Veeva Systems Emerson LabVantage Solutions Marken MasterControl QuickSTAT Siemens Stafa Cellular Therapy Steiner STEMSOFT Software TECHNIDATA Thermo Fisher Scientific KEY QUESTIONS ANSWERED IN THIS REPORT How many companies are currently engaged in this market? Which are the leading companies in this market? What kind of partnership models are commonly adopted by industry stakeholders? What are the factors that are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. ADDITIONAL BENEFITS Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell and Gene Therapy Supply Chain CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Wall Street Journal
25 minutes ago
- Wall Street Journal
Wall Street's Bargain-Hunters Are Back
Sky-high valuations for tech heavyweights have left investors searching for alternatives. Plus, President Trump's trade policies haven't affected all companies the same way, creating winners (and losers) for investors to discover.
Forbes
25 minutes ago
- Forbes
Small Businesses Love AI — But Most Are Missing What Matters
From marketing to discoverability, AI is transforming small business — but what's happening behind ... More the scenes may matter more. It's never been easier to generate a social post, draft a newsletter, or spin up a polished website using AI like it is today. And many small businesses are embracing AI, automating marketing tasks, building faster sites and scaling campaigns that once required full teams. But according to two executives shaping AI adoption for small businesses — Itai Sadan, cofounder and CEO of Duda, and Louis Gutierrez, director of AI at Constant Contact — a more complicated picture is emerging. While the excitement about AI-powered automation is real, most SMBs are not yet ready to combat the challenges that come with using AI. Reality Versus Expectations At Duda, which powers more than a million small business websites, nearly 45% of new sites now use at least one AI assistant, according to Sadan. From SEO optimization to content generation, the tools are being adopted at a striking rate. 'We're seeing this huge uptake, especially in areas like image alt text generation or SEO automation,' Sadan said. 'What used to take hours can now be done in minutes with a single click.' Constant Contact is seeing a similar pattern. Gutierrez noted that many of their small business users are 'doing more with less' — wearing multiple hats, streamlining content workflows and using AI to personalize customer communication at scale. 'AI lets them scale, yes,' Gutierrez said, 'but it also allows them to focus on what they're passionate about and delegate the rest.' But these gains come with a shift in customer expectations. As AI makes marketing faster and more accessible, customers now expect more personalized experiences, faster turnaround and seamless execution. The pressure on small businesses to perform like enterprises — without the same resources — is growing by no small margins. Real Infrastructure Needs While AI appears magical on the surface, the infrastructure underneath is anything but. Gutierrez, who also teaches a course in explainable AI at UT Austin, likened AI models to perishable goods. 'Think of models like a can of beans,' he told me. 'There's an expiration date even if it's not visible. Over time, their performance degrades. And without infrastructure that allows you to update, retrain, or replace them, you're flying blind.' That's why Constant Contact's biggest AI bet isn't a shiny front-end feature but infrastructure. From fine-tuning pipelines to monitoring model drift, the company is building the capacity to stay agile regardless of whether today's dominant model is replaced tomorrow. Sadan sees infrastructure as equally essential. Duda recently rolled out MCP-powered AI copilots that allow users to launch, maintain and edit websites using natural language. In other words, users can now talk to the website builder like they would a human assistant — asking it to update content, fix layouts, or add features just by typing in plain language. But under the hood, it works by chaining API calls, model queries and platform logic into one coherent action layer. 'These are real agentic systems,' Sadan said. 'But if you don't have the data structures, APIs, and schema mapping in place, none of it works. The AI can't fake its way through broken plumbing.' Governance Isn't Optional Anymore Despite the impressive front-end capabilities, both leaders warn that AI without governance is a disaster waiting to happen, especially for small teams with limited oversight. 'At some point, a staff member will drop sensitive customer data into ChatGPT,' Sadan said. 'Not because they're careless but because there are no rules.' Gutierrez agreed, noting that that's why Constant Contact established an internal AI governance committee to vet AI tools for ethics, privacy, security and standardization. The challenge, he explained, isn't just performance. It's what happens when tools fail or deliver biased results. 'Everything's easy when you prototype on your laptop,' he said. 'But the second a model goes into production, it behaves in ways you never imagined. That's where governance matters most.' Without a clear policy, companies risk leaking data, overpromising capabilities, or baking systemic bias into customer-facing tools. And while governance may sound like an enterprise luxury, both executives say it's a small-business necessity. The New SEO War Perhaps the most overlooked trend in small business AI is how people find products and services in the first place. While Google still dominates traffic, Sadan said traffic from ChatGPT citations is 'growing at a staggering pace.' Duda is betting heavily on this shift. In addition to automating SEO tasks, the company is investing in AI discoverability features that optimize websites for how LLMs index and interpret them. From FAQ schemas to product data markup, the goal is to rank in the age of AI-powered search, not just traditional queries. 'This is like the early days of Facebook for businesses,' Sadan said. 'If you understand how to ride the wave early, you can grow faster than your competitors, all for less.' Gutierrez, meanwhile, is watching another shift: Vibe coding — the ability to build full software applications using natural language. 'It's turning non-coders into full-stack developers,' he said. 'In a few years, every small business could build their own CRM or booking system just by describing what they want.' Wielding AI Well Both executives agree: AI won't replace small businesses, but using it poorly could put them at risk. Gutierrez warned against the current trend of overpromising what AI can do. 'I'm in vendor meetings all the time,' he said. 'Too many pitch AI as a magic box that does everything. That's dangerous.' Sadan echoed this sentiment, adding that the biggest mistake small businesses make is adopting tools without evaluating their actual productivity gains. 'Try the tool,' he said. 'If it doesn't make your day faster or your work better, it's not worth it, no matter what the marketing says.' What's missing from many AI adoption stories is restraint. It's not enough to use AI; you have to understand what it's good at, what it's not and how to build around that reality. That means investing in infrastructure, enforcing governance and designing for a future where autonomous discovery and interaction may define who thrives and who doesn't. As Gutierrez put it: 'You don't win by adding AI to your toolset. You win by building a business that knows how to wield it.'
